Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
271 hedge funds and large institutions have $4.57B invested in Clovis Oncology, Inc. in 2017 Q2 according to their latest regulatory filings, with 73 funds opening new positions, 109 increasing their positions, 72 reducing their positions, and 31 closing their positions.
135% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 31
100% more funds holding in top 10
Funds holding in top 10: 8 → 16 (+8)
93% more call options, than puts
Call options by funds: $300M | Put options by funds: $156M
63% more capital invested
Capital invested by funds: $2.8B → $4.57B (+$1.77B)
51% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 72
18% more funds holding
Funds holding: 229 → 271 (+42)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$129M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$108M |
| 3 |
Jennison Associates
New York
|
+$50M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$42.1M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$84.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$48.3M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$39.7M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$38.9M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$34.6M |
CLVS Hedge Fund Activity: Q2 2017 in Review
271 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q2 2017, worth a combined $4.57B — up 63% from $2.8B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new CLVS positions and 31 closed out — a net gain of 42 holders — while 109 added to existing stakes and 72 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $129M. The largest seller was Wellington Management Group, exiting entirely with an estimated $84.8M sold.
- 271 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q2 2017, up from 229 in Q1 2017.
- Funds reported $4.57B of Clovis Oncology, Inc. stock for Q2 2017, up 63% quarter-over-quarter.
- 73 funds opened new Clovis Oncology, Inc. positions in Q2 2017 and 31 closed out, a net change of +42 holders.
- The largest Clovis Oncology, Inc. buyer in Q2 2017 was OrbiMed, an estimated $129M added.
- The largest Clovis Oncology, Inc. seller in Q2 2017 was Wellington Management Group, an estimated $84.8M sold.
Based on aggregated 13F filings for Q2 2017.